

Kurt Huber

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6192484/publications.pdf>

Version: 2024-02-01

205
papers

25,207
citations

34493

54
h-index

7836

155
g-index

206
all docs

206
docs citations

206
times ranked

19740
citing authors

#	ARTICLE	IF	CITATIONS
1	Resumption of Antiplatelet Therapy after Major Bleeding. <i>Thrombosis and Haemostasis</i> , 2023, 123, 135-149.	1.8	4
2	PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 28-38.	1.4	39
3	Long-term outcome in patients with takotsubo syndrome. <i>Wiener Klinische Wochenschrift</i> , 2022, 134, 261-268.	1.0	8
4	The year in cardiovascular medicine 2021: acute cardiovascular care and ischaemic heart disease. <i>European Heart Journal</i> , 2022, 43, 800-806.	1.0	7
5	OUP accepted manuscript. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2022, , .	0.4	0
6	OUP accepted manuscript. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2022, , .	0.4	3
7	Basic mechanisms in cardiogenic shock: part 1 – definition and pathophysiology. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2022, 11, 356-365.	0.4	8
8	Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute Cardiovascular Care and the Asia-Pacific Heart Rhythm Society. <i>Europace</i> , 2022, 24, 1844-1871.	0.7	11
9	Biomarkers Associated with Cardiovascular Disease in COVID-19. <i>Cells</i> , 2022, 11, 922.	1.8	12
10	Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Per-Protocol Analysis of the GLOBAL LEADERS Trial. <i>Journal of the American Heart Association</i> , 2022, 11, e024291.	1.6	4
11	Balance of Benefit and Risk of Ticagrelor in Patients With Diabetes and Stable Coronary Artery Disease According to Bleeding Risk Assessment With the CRUSADE Score: Data From THEMIS and THEMIS PCI. <i>American Heart Journal</i> , 2022, 249, 23-23.	1.2	1
12	Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 707-716.	1.4	5
13	Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study. <i>EuroIntervention</i> , 2022, 17, 1330-1339.	1.4	5
14	Dual antiplatelet therapy duration after percutaneous coronary intervention using drug eluting stents in high bleeding risk patients: A systematic review and meta-analysis. <i>American Heart Journal</i> , 2022, 250, 1-10.	1.2	6
15	The clinical approach to diagnosing peri-procedural myocardial infarction after percutaneous coronary interventions according to the fourth universal definition of myocardial infarction – from the study group on biomarkers of the European Society of Cardiology (ESC) Association for Acute Cardiovascular Care (ACVC). <i>Biomarkers</i> , 2022, 27, 407-417.	0.9	3
16	Pharmacologic modulation of intracellular Na ⁺ concentration with ranolazine impacts inflammatory response in humans and mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	3
17	Gender-based differences of copeptin alone or combined with troponin for early rule-out of non-ST-elevation myocardial infarction. <i>American Journal of Emergency Medicine</i> , 2021, 45, 248-253.	0.7	6
18	Effect of marathon and ultra-marathon on inflammation and iron homeostasis. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2021, 31, 542-552.	1.3	9

#	ARTICLE	IF	CITATIONS
19	Clinical Outcomes According to ECG Presentations in Infarct-Related Cardiogenic Shock in the Culprit Lesion Only PCI vs Multivessel PCI in Cardiogenic Shock Trial. <i>Chest</i> , 2021, 159, 1415-1425.	0.4	4
20	Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry. <i>Internal and Emergency Medicine</i> , 2021, 16, 591-599.	1.0	4
21	ESC Study Group on Cardiac Biomarkers of the Association for Acute Cardiovascular Care: A fond farewell at the retirement of CKMB. <i>European Heart Journal</i> , 2021, 42, 2260-2264.	1.0	23
22	Effects of Nicorandil on Inflammation, Apoptosis and Atherosclerotic Plaque Progression. <i>Biomedicines</i> , 2021, 9, 120.	1.4	15
23	Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 444-456.	1.1	27
24	2020 Update of the quality indicators for acute myocardial infarction: a position paper of the Association for Acute Cardiovascular Care: the study group for quality indicators from the ACVC and the NSTEMI-ACS guideline group. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 224-233.	0.4	54
25	Critical appraisal of the 2020 ESC guideline recommendations on diagnosis and risk assessment in patients with suspected non-ST-segment elevation acute coronary syndrome. <i>Clinical Research in Cardiology</i> , 2021, 110, 1353-1368.	1.5	8
26	Comparison of Investigator-Reported and Clinical Event Committee-Adjudicated Outcome Events in GLASSY. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e006581.	0.9	10
27	Cardiovascular biomarkers in patients with COVID-19. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 310-319.	0.4	44
28	Scores for outcome prediction in patients admitted with cardiogenic shock. <i>European Heart Journal</i> , 2021, 42, 2353-2355.	1.0	4
29	Joint EAPCI/ACVC expert consensus document on percutaneous ventricular assist devices. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 570-583.	0.4	38
30	Clopidogrel vs. prasugrel vs. ticagrelor in patients with acute myocardial infarction complicated by cardiogenic shock: a pooled IABP-SHOCK II and CULPRIT-SHOCK trial sub-analysis. <i>Clinical Research in Cardiology</i> , 2021, 110, 1493-1503.	1.5	3
31	Reclassification, Thromboembolic, and Major Bleeding Outcomes Using Different Estimates of Renal Function in Anticoagulated Patients With Atrial Fibrillation: Insights From the PREFER-in-AF and PREFER-in-AF Prolongation Registries. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e006852.	0.9	11
32	Meta-Analysis of Anticoagulation Therapy for the Prevention of Cardiovascular Events in Patients With Peripheral Arterial Disease. <i>American Journal of Cardiology</i> , 2021, 148, 165-171.	0.7	0
33	Pharmacological inhibition of fatty acid oxidation reduces atherosclerosis progression by suppression of macrophage NLRP3 inflammasome activation. <i>Biochemical Pharmacology</i> , 2021, 190, 114634.	2.0	11
34	Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. <i>European Heart Journal</i> , 2021, 42, 4683-4693.	1.0	18
35	Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute Cardiovascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA). <i>Cardiovascular Research</i> , 2021, 117, 2705-2729.	1.8	95
36	Comparison of risk prediction models in infarct-related cardiogenic shock. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 890-897.	0.4	11

#	ARTICLE	IF	CITATIONS
37	Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre-specified Analysis of the GLOBAL LEADERS Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e015560.	1.6	18
38	Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. <i>European Heart Journal</i> , 2021, 42, 4624-4634.	1.0	54
39	Impact of Center Volume on Outcomes in Myocardial Infarction Complicated by Cardiogenic Shock: A CULPRIT-SHOCK Substudy. <i>Journal of the American Heart Association</i> , 2021, 10, e021150.	1.6	1
40	Biomarkers of coagulation and fibrinolysis in acute myocardial infarction: a joint position paper of the Association for Acute Cardiovascular Care and the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 343-355.	0.4	9
41	Improvement of outcome prediction of hospitalized patients with COVID-19 by a dual marker strategy using high-sensitive cardiac troponin I and copeptin. <i>Clinical Research in Cardiology</i> , 2021, , 1.	1.5	3
42	Release of mitochondrial DNA is associated with mortality in severe acute heart failure. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 419-428.	0.4	14
43	Impact of preprocedural TIMI flow on clinical outcome in low-risk patients with ST-elevation myocardial infarction: Results from the ATLANTIC study. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 494-500.	0.7	12
44	Predictors of transportation delay in patients with suspected ST-elevation-myocardial infarction in the VIENNA-STEMI network. <i>Clinical Research in Cardiology</i> , 2020, 109, 393-399.	1.5	9
45	Toll-like receptor 2 and 9 expression on circulating neutrophils is associated with increased mortality in critically ill patients. <i>Shock</i> , 2020, 54, 35-43.	1.0	6
46	Smoking and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients: a substudy from the randomized TROPICAL-ACS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 372-381.	1.4	7
47	Response to: "Arrhythmia paradox in patients with familial hypercholesterolemia". <i>Journal of Clinical Lipidology</i> , 2020, 14, 154-155.	0.6	0
48	Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 918-929.	1.5	3
49	Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of Ticagrelor in STEMI: A Subanalysis of the ATLANTIC Trial. <i>Thrombosis and Haemostasis</i> , 2020, 120, 065-074.	1.8	11
50	Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. <i>European Heart Journal</i> , 2020, 41, 3533-3545.	1.0	93
51	Von Willebrand Factor and ADAMTS13 and long-term outcomes in patients undergoing percutaneous coronary intervention. <i>Thrombosis Research</i> , 2020, 196, 31-37.	0.8	6
52	The Association for Acute Cardiovascular Care. <i>European Heart Journal</i> , 2020, 41, 3977-3978.	1.0	0
53	Changes in Circulating Extracellular Vesicles in Patients with ST-Elevation Myocardial Infarction and Potential Effects of Remote Ischemic Conditioning: A Randomized Controlled Trial. <i>Biomedicines</i> , 2020, 8, 218.	1.4	12
54	Rationale and design of the MULTISTARS AMI Trial: A randomized comparison of immediate versus staged complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease. <i>American Heart Journal</i> , 2020, 228, 98-108.	1.2	11

#	ARTICLE	IF	CITATIONS
55	Impact of white blood cell count on clinical outcomes in patients treated with aspirin-free ticagrelor monotherapy after percutaneous coronary intervention: insights from the GLOBAL LEADERS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, , .	1.4	10
56	Evaluation of the Age, Biomarkers, and Clinical Historyâ€“Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials. <i>JAMA Network Open</i> , 2020, 3, e2015943.	2.8	5
57	Effects of ON-Hours Versus OFF-Hours Admission on Outcome in Patients With Myocardial Infarction and Cardiogenic Shock. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009562.	1.4	5
58	An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial. <i>JAMA Cardiology</i> , 2020, 5, 709.	3.0	63
59	Covid-19: implications for prehospital, emergency and hospital care in patients with acute coronary syndromes. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 222-228.	0.4	17
60	Coronary interventions in Austria, Germany, and Switzerland. <i>European Heart Journal</i> , 2020, 41, 2599-2600.	1.0	7
61	EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic. <i>European Heart Journal</i> , 2020, 41, 1839-1851.	1.0	106
62	Epinephrine treatment but not time to ROSC is associated with intestinal injury in patients with cardiac arrest. <i>Resuscitation</i> , 2020, 155, 32-38.	1.3	6
63	Thromboembolic and bleeding risk in obese patients with atrial fibrillation according to different anticoagulation strategies. <i>International Journal of Cardiology</i> , 2020, 318, 67-73.	0.8	11
64	Comparing TEEâ€“vs Nonâ€“TEEâ€“guided cardioversion of atrial fibrillation: The ENSUREâ€“AF trial. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13221.	1.7	2
65	Effect of concomitant antiplatelet agents on clinical outcomes in the edoxaban vs warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomized trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 1374-1380.	1.5	4
66	Sex-Specific Management in Patients With Acute Myocardial Infarction and Cardiogenic Shock. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008537.	1.4	35
67	Acute Cardiovascular Care Association position statement for the diagnosis and treatment of patients with acute myocardial infarction complicated by cardiogenic shock: A document of the Acute Cardiovascular Care Association of the European Society of Cardiology. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 183-197.	0.4	126
68	Prognostic Impact of Active Mechanical Circulatory Support in Cardiogenic Shock Complicating Acute Myocardial Infarction, Results from the Culprit-Shock Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 1976.	1.0	9
69	The ISTH DIC score predicts outcome in non-septic patients admitted to a cardiovascular intensive care unit. <i>European Journal of Internal Medicine</i> , 2020, 79, 37-42.	1.0	11
70	Outcomes Associated with Respiratory Failure for Patients with Cardiogenic Shock and Acute Myocardial Infarction: A Substudy of the CULPRIT-SHOCK Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 860.	1.0	8
71	Impact of ultra-marathon and marathon on biomarkers of myocyte necrosis and cardiac congestion: a prospective observational study. <i>Clinical Research in Cardiology</i> , 2020, 109, 1366-1373.	1.5	6
72	Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2403-2413.	1.2	60

#	ARTICLE	IF	CITATIONS
73	Ticagrelor With or Without Aspirin After ComplexÂPCI. Journal of the American College of Cardiology, 2020, 75, 2414-2424.	1.2	122
74	Cardiac Arrest in the COVID-19 Era. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 239-240.	0.4	14
75	Pre-hospital management of patients with chest pain and/or dyspnoea of cardiac origin. A position paper of the Acute Cardiovascular Care Association (ACCA) of the ESC.. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 59-81.	0.4	51
76	Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction. JAMA Cardiology, 2020, 5, 952.	3.0	56
77	Intestinal Fatty Acid Binding Protein is Associated With Mortality in Patients With Acute Heart Failure or Cardiogenic Shock. Shock, 2019, 51, 410-415.	1.0	17
78	2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm So. Europace, 2019, 21, 192-193.	0.7	209
79	Management of Antithrombotic Therapy in Atrial Fibrillation Patients UndergoingÂPCI. Journal of the American College of Cardiology, 2019, 74, 83-99.	1.2	126
80	Gender and Outcomes following Guided De-Escalation of Antiplatelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Gender Substudy. Thrombosis and Haemostasis, 2019, 119, 1527-1538.	1.8	7
81	Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting. Journal of the American College of Cardiology, 2019, 74, 2223-2234.	1.2	101
82	Characteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 382	0.7	18
83	Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. Journal of Thrombosis and Thrombolysis, 2019, 48, 563-569.	1.0	11
84	Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention. Circulation, 2019, 140, 1921-1932.	1.6	57
85	Ticagrelor with or without Aspirin in High-Risk Patients after PCI. New England Journal of Medicine, 2019, 381, 2032-2042.	13.9	683
86	Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation. American Journal of Medicine, 2019, 132, 749-757.e5.	0.6	48
87	Prognostic Impact of Atrial Fibrillation in Acute Myocardial Infarction and Cardiogenic Shock. Circulation: Cardiovascular Interventions, 2019, 12, e007661.	1.4	18
88	Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel: a pre-specified exploratory analysis from the TROPICAL-ACS trial. European Heart Journal, 2019, 40, 1942-1951.	1.0	41
89	Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-Study (GLASSY). BMJ Open, 2019, 9, e026053.	0.8	18
90	Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention of thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF). BMJ Open, 2019, 9, e022478.	0.8	50

#	ARTICLE	IF	CITATIONS
91	Guided de-escalation of DAPT in acute coronary syndrome patients undergoing percutaneous coronary intervention with BVS implantation: a post-hoc analysis from the randomized TROPICAL-ACS trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 427-435.	1.0	3
92	Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation. <i>Heart</i> , 2019, 105, 235-242.	1.2	19
93	Intraaortic Balloon Pump in Cardiogenic Shock Complicating Acute Myocardial Infarction. <i>Circulation</i> , 2019, 139, 395-403.	1.6	246
94	Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 173-183.	1.0	23
95	High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure. <i>International Journal of Cardiology</i> , 2019, 277, 166-172.	0.8	32
96	Pre-hospital administration of ticagrelor in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: A sub-analysis of the ATLANTIC trial. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, E369-E377.	0.7	4
97	Prognostic impact of familial hypercholesterolemia on long-term outcomes in patients undergoing percutaneous coronary intervention. <i>Journal of Clinical Lipidology</i> , 2019, 13, 115-122.	0.6	11
98	Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. <i>Circulation</i> , 2019, 139, 1483-1492.	1.6	533
99	ECG Changes and Their Prognostic Impact in Patients With Takotsubo Syndrome. <i>Cardiology and Cardiovascular Medicine</i> , 2019, 03, .	0.1	4
100	Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. <i>European Heart Journal</i> , 2018, 39, 1672-1686f.	1.0	106
101	Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease. <i>Circulation</i> , 2018, 138, 756-766.	1.6	200
102	Circulating microRNAs identify patients at increased risk of in-stent restenosis after peripheral angioplasty with stent implantation. <i>Atherosclerosis</i> , 2018, 269, 197-203.	0.4	31
103	Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 75-81.	1.4	9
104	Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure. <i>Circulation</i> , 2018, 137, 286-297.	1.6	157
105	Uric acid is associated with long-term adverse cardiovascular outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention. <i>Atherosclerosis</i> , 2018, 270, 173-179.	0.4	46
106	How is cardiac troponin released from injured myocardium?. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 553-560.	0.4	179
107	Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy. <i>International Journal of Cardiology</i> , 2018, 265, 141-147.	0.8	38
108	Is Treatment of ST-Segment-Elevation Myocardial Infarction Patients With Ticagrelor or Other P2Y 12 Inhibitors Before Primary Percutaneous Coronary Intervention a Strategy Without Benefit?. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006555.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Impact of age on short- and long-term mortality of patients with ST-elevation myocardial infarction in the VIENNA STEMI network. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 172-181.	1.0	20
110	Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial. <i>American Heart Journal</i> , 2018, 197, 133-141.	1.2	17
111	Duration of ischemia and treatment effects of pre- versus in-hospital ticagrelor in patients with ST-segment elevation myocardial infarction: Insights from the ATLANTIC study. <i>American Heart Journal</i> , 2018, 196, 56-64.	1.2	10
112	Midregional pro-A-type natriuretic peptide as part of a dual biomarker strategy for the early rule out of non-ST segment elevation acute coronary syndrome – The WilCop study. <i>International Journal of Cardiology</i> , 2018, 273, 243-248.	0.8	2
113	Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries. <i>International Journal of Cardiology</i> , 2018, 270, 160-166.	0.8	24
114	Outcomes of Patients Receiving Downstream Revascularization After Initial Medical Management for Non-ST-Segment Elevation Acute Coronary Syndromes (From the TRILOGY ACS Trial). <i>American Journal of Cardiology</i> , 2018, 122, 1322-1329.	0.7	2
115	Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial. <i>European Heart Journal</i> , 2018, 39, 2749-2758.	1.0	40
116	Current Definitions of Non-ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 865-867.	1.1	0
117	One-Year Outcomes after PCI Strategies in Cardiogenic Shock. <i>New England Journal of Medicine</i> , 2018, 379, 1699-1710.	13.9	303
118	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. <i>Lancet</i> , The, 2018, 392, 940-949.	6.3	555
119	Clinical predictors of patient related delay in the VIENNA ST-elevation myocardial infarction network and impact on long-term mortality. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 254-261.	0.4	28
120	How to use D-dimer in acute cardiovascular care. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 69-80.	0.4	60
121	Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: An analysis from EARLY ACS. <i>International Journal of Cardiology</i> , 2017, 232, 264-270.	0.8	7
122	Monocyte subsets in myocardial infarction: A review. <i>International Journal of Cardiology</i> , 2017, 231, 47-53.	0.8	20
123	Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites. <i>American Journal of Medicine</i> , 2017, 130, 1170-1176.	0.6	8
124	Temporal Biomarker Profiling Reveals Longitudinal Changes in Risk of Death or Myocardial Infarction in Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Clinical Chemistry</i> , 2017, 63, 1214-1226.	1.5	9
125	PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. <i>New England Journal of Medicine</i> , 2017, 377, 2419-2432.	13.9	764
126	PAI-1 (Plasminogen Activator Inhibitor-1) Expression Renders Alternatively Activated Human Macrophages Proteolytically Quiescent. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 1913-1922.	1.1	22

#	ARTICLE	IF	CITATIONS
127	Interruption of non-vitamin K antagonist anticoagulants in patients undergoing planned invasive procedures: how long is long enough?. <i>European Heart Journal</i> , 2017, 38, 2440-2443.	1.0	6
128	Usefulness of Elevated Levels of Growth Differentiation Factor-15 to Classify Patients With Acute Coronary Syndrome Having Percutaneous Coronary Intervention Who Would Benefit from High-Dose Statin Therapy. <i>American Journal of Cardiology</i> , 2017, 120, 747-752.	0.7	6
129	Impact of time of admission on short- and long-term mortality in the Vienna STEMI registry. <i>International Journal of Cardiology</i> , 2017, 244, 1-6.	0.8	10
130	Gender differences in short- and long-term mortality in the Vienna STEMI registry. <i>International Journal of Cardiology</i> , 2017, 244, 303-308.	0.8	31
131	Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin. <i>JAMA Cardiology</i> , 2017, 2, 1385.	3.0	89
132	Urokinase plasminogen activator protects cardiac myocytes from oxidative damage and apoptosis via hOGG1 induction. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2017, 22, 1048-1055.	2.2	19
133	Quality indicators for acute myocardial infarction: A position paper of the Acute Cardiovascular Care Association. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 34-59.	0.4	109
134	Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. <i>Lancet, The</i> , 2017, 390, 1747-1757.	6.3	443
135	Bivalirudin in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: uncertainties almost clarified. <i>EuroIntervention</i> , 2017, 12, 1930-1932.	1.4	0
136	Relationship Between Arterial Access and Outcomes in STâ€Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STRategic Reperfusion Early After Myocardial Infarction (STREAM) Study. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	5
137	MicroRNAs as circulating biomarkers in acute coronary syndromes: A review. <i>Vascular Pharmacology</i> , 2016, 81, 15-21.	1.0	31
138	Copeptin for the early rule-out of non-ST-elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2016, 223, 797-804.	0.8	26
139	Monocyte subset distribution is associated with mortality in critically ill patients. <i>Thrombosis and Haemostasis</i> , 2016, 116, 949-957.	1.8	19
140	Systematic screening for cardiovascular risk at pharmacies. <i>Open Heart</i> , 2016, 3, e000497.	0.9	7
141	Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated by cardiogenic shock: Design and rationale of CULPRIT-SHOCK trial. <i>American Heart Journal</i> , 2016, 172, 160-169.	1.2	93
142	Electrocardiogram changes and wall motion abnormalities in the acute phase of Tako-Tsubo syndrome. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016, 5, 481-488.	0.4	14
143	Infarct Size, Shock, and Heart Failure: Does Reperfusion Strategy Matter in Early Presenting Patients With STâ€Segment Elevation Myocardial Infarction?. <i>Journal of the American Heart Association</i> , 2015, 4, e002049.	1.6	10
144	Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing. <i>Thrombosis and Haemostasis</i> , 2015, 114, 459-468.	1.8	50

#	ARTICLE	IF	CITATIONS
145	Levosimendan exerts anti-inflammatory effects on cardiac myocytes and endothelial cells in vitro. <i>Thrombosis and Haemostasis</i> , 2015, 113, 350-362.	1.8	26
146	Platelet function testing in acute cardiac care – is there a role for prediction or prevention of stent thrombosis and bleeding?. <i>Thrombosis and Haemostasis</i> , 2015, 113, 221-230.	1.8	33
147	Mitochondrial DNA and Toll-Like Receptor-9 Are Associated With Mortality in Critically Ill Patients. <i>Critical Care Medicine</i> , 2015, 43, 2633-2641.	0.4	60
148	Platelets, inflammation and anti-inflammatory drugs in ACS and CAD. <i>Thrombosis and Haemostasis</i> , 2015, 114, 446-448.	1.8	9
149	One-year mortality in patients with acute ST-elevation myocardial infarction in the Vienna STEMI registry. <i>Wiener Klinische Wochenschrift</i> , 2015, 127, 535-542.	1.0	11
150	Prasugrel in Clopidogrel Nonresponders. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1571-1573.	1.1	1
151	Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. <i>European Heart Journal</i> , 2014, 35, 209-215.	1.0	224
152	Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries. <i>European Heart Journal</i> , 2014, 35, 1957-1970.	1.0	275
153	Influence of High-Dose Highly Efficient Statins on Short-Term Mortality in Patients Undergoing Percutaneous Coronary Intervention With Stenting for Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2014, 113, 1099-1104.	0.7	21
154	How can we optimize the processes of care for acute coronary syndromes to improve outcomes?. <i>American Heart Journal</i> , 2014, 168, 622-631.e2.	1.2	16
155	Prehospital Ticagrelor in ST-Segment Elevation Myocardial Infarction. <i>New England Journal of Medicine</i> , 2014, 371, 1016-1027.	13.9	538
156	The organization, function, and outcomes of ST-elevation myocardial infarction networks worldwide: current state, unmet needs and future directions. <i>European Heart Journal</i> , 2014, 35, 1526-1532.	1.0	65
157	Bivalirudin Started during Emergency Transport for Primary PCI. <i>New England Journal of Medicine</i> , 2013, 369, 2207-2217.	13.9	443
158	Enhancing the efficacy of delivering reperfusion therapy: A European and North American experience with ST-segment elevation myocardial infarction networks. <i>American Heart Journal</i> , 2013, 165, 123-132.	1.2	31
159	Fibrinolysis or Primary PCI in ST-Segment Elevation Myocardial Infarction. <i>New England Journal of Medicine</i> , 2013, 368, 1379-1387.	13.9	595
160	Stress-induced cardiomyopathy (Tako-Tsubo syndrome) in Austria. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2013, 2, 137-146.	0.4	27
161	High on-treatment platelet reactivity - why should we be concerned?. <i>Thrombosis and Haemostasis</i> , 2013, 109, 789-791.	1.8	7
162	The Role of Platelets in Athero-Thrombotic Events. <i>Current Pharmaceutical Design</i> , 2012, 18, 5197-5214.	0.9	57

#	ARTICLE	IF	CITATIONS
163	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2012, 33, 2569-2619.	1.0	5,034
164	Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2012, 366, 20-33.	13.9	701
165	Optimizing reperfusion therapy in acute ST-elevation myocardial infarction by a pharmaco-invasive treatment approach in a well-organized network. <i>European Heart Journal</i> , 2012, 33, 1184-1186.	1.0	4
166	Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial. <i>Clinical Research in Cardiology</i> , 2012, 101, 305-312.	1.5	119
167	Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents. <i>Fundamental and Clinical Pharmacology</i> , 2012, 26, 2-10.	1.0	7
168	Genetic variability in response to clopidogrel therapy and its clinical implications. <i>Thrombosis and Haemostasis</i> , 2011, 105, S55-S59.	1.8	22
169	Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: Similarities and dissimilarities between North America and Europe. <i>Thrombosis and Haemostasis</i> , 2011, 106, 569-571.	1.8	70
170	Platelet function variability and non-genetic causes. <i>Thrombosis and Haemostasis</i> , 2011, 105, S60-S66.	1.8	30
171	The role of fibrinolysis in the era of primary percutaneous coronary intervention. <i>Thrombosis and Haemostasis</i> , 2011, 105, 390-395.	1.8	17
172	Bleeding risk assessment and management in atrial fibrillation patients. <i>Thrombosis and Haemostasis</i> , 2011, 106, 997-1011..	1.8	234
173	Functional testing methods for the antiplatelet effects of aspirin. <i>Biomarkers in Medicine</i> , 2011, 5, 31-42.	0.6	31
174	Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. <i>European Heart Journal</i> , 2011, 32, 1854-1864.	1.0	343
175	Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation. <i>Circulation</i> , 2011, 123, 2363-2372.	1.6	1,035
176	Platelet-monocyte cross talk and tissue factor expression in stable angina vs. unstable angina/non ST-elevation myocardial infarction. <i>Platelets</i> , 2011, 22, 530-536.	1.1	16
177	Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. <i>Europace</i> , 2011, 13, 723-746.	0.7	197
178	Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation. <i>Thrombosis and Haemostasis</i> , 2010, 104, 1211-1218.	1.8	41
179	Network models for large cities: the European experience. <i>Heart</i> , 2010, 96, 164-169.	1.2	36
180	Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial. <i>European Heart Journal</i> , 2010, 31, 1708-1716.	1.0	63

#	ARTICLE	IF	CITATIONS
181	Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting. <i>Thrombosis and Haemostasis</i> , 2010, 103, 13-28.	1.8	292
182	Recommendations for the use of cardiac troponin measurement in acute cardiac care. <i>European Heart Journal</i> , 2010, 31, 2197-2204.	1.0	533
183	Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2010, 31, 2501-2555.	1.0	2,649
184	Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. <i>European Heart Journal</i> , 2010, 31, 943-957.	1.0	548
185	A European perspective on improving acute systems of care in STEMI: we know what to do, but how can we do it?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 708-714.	3.3	27
186	Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. <i>European Heart Journal</i> , 2008, 29, 2909-2945.	1.0	2,128
187	Thienopyridines in cardiovascular disease: Focus on Clopidogrel resistance. <i>Thrombosis and Haemostasis</i> , 2007, 97, 385-393.	1.8	95
188	Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction*. <i>Critical Care Medicine</i> , 2006, 34, 2035-2042.	0.4	130
189	Implementation of Guidelines Improves the Standard of Care. <i>Circulation</i> , 2006, 113, 2398-2405.	1.6	328
190	Platelet activation and high tissue factor level predict acute stent thrombosis in pig coronary arteries: Prothrombotic response of drug-eluting or bare stent implantation within the first 24 hours. <i>Thrombosis and Haemostasis</i> , 2006, 96, 202-209.	1.8	17
191	Pre-hospital reperfusion therapy: a strategy to improve therapeutic outcome in patients with ST-elevation myocardial infarction. <i>European Heart Journal</i> , 2005, 26, 2063-2074.	1.0	69
192	Catecholamines potentiate LPS-induced expression of MMP-1 and MMP-9 in human monocytes and in the human monocytic cell line U937: possible implications for perioperative plaque instability. <i>FASEB Journal</i> , 2004, 18, 603-605.	0.2	66
193	Association between plasmin activation system and intravascular ultrasound signs of plaque instability in patients with unstable angina and non-ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2004, 147, 158-164.	1.2	30
194	Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion ? results of the Austrian multi-centre randomized ReoPro-BRIDGING Study. <i>European Heart Journal</i> , 2004, 25, 2125-2133.	1.0	83
195	Multiple organ failure in patients with cardiogenic shock is associated with high plasma levels of interleukin-6. <i>Critical Care Medicine</i> , 2002, 30, 1987-1994.	0.4	116
196	Plasminogen activator inhibitor type-1 (part two): role for failure of thrombolytic therapy. PAI-1 resistance as a potential benefit for new fibrinolytic agents. , 2001, 11, 195-202.		20
197	Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease. , 2001, 11, 183-193.		64
198	Effects of the 5-HT3 antagonist cilansetron vs placebo on phasic sigmoid colonic motility in healthy man: a double-blind crossover trial. <i>British Journal of Clinical Pharmacology</i> , 2000, 49, 429-436.	1.1	16

#	ARTICLE	IF	CITATIONS
199	The decanucleotide polymorphism in the factor VII promoter predicts factor VII plasma levels but not the risk of acute coronary syndromes. <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 10, 23-28.	1.0	5
200	Plasmin activation system in restenosis: role in pathogenesis and clinical prediction?. <i>Journal of Thrombosis and Thrombolysis</i> , 1999, 7, 277-285.	1.0	24
201	Concentration of Endogenous tPA Antigen in Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998, 18, 1634-1642.	1.1	42
202	Antifibrinolytic Properties of the Vascular Wall. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 723-730.	1.1	16
203	Assessment of left ventricular function: comparison between radionuclide angiography and semiquantitative two-dimensional echocardiographic analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996, 23, 1613-1618.	2.2	20
204	Evaluation of Fibrinolytic Capacity in Plasma during Thrombolytic Therapy with Single (scu-PA) or Two-chain Urokinase Type Plasminogen Activator (tcu-PA) by a Combined Assay System for Urokinase Type Plasminogen Activator Antigen and Function. <i>Thrombosis and Haemostasis</i> , 1989, 61, 289-293.	1.8	20
205	The cardiac arrest centre for the treatment of sudden cardiac arrest due to presumed cardiac cause: aims, function, and structure: position paper of the ACVC association of the ESC, EAPCI, EHRA, ERC, EUSEM, and ESICM. <i>European Heart Journal: Acute Cardiovascular Care</i> , 0, , .	0.4	9